Clinical Trial Update: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial tested sirolimus, tacrolimus, and antithymocyte globulin for preventing graft-versus-host disease in patients undergoing donor stem cell tran…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Leukemia
• Lymphoma
• Multiple Myeloma and Plasma Cell Neoplasm
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myelofibrosis
• Myeloproliferative Disorders

Drugs mentioned

• Prograf (Tacrolimus)
• Rapamune (sirolimus)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-08-12